Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Aug;40(8):1846–1854. doi: 10.1128/aac.40.8.1846

4-aminoquinoline analogs of chloroquine with shortened side chains retain activity against chloroquine-resistant Plasmodium falciparum.

R G Ridley 1, W Hofheinz 1, H Matile 1, C Jaquet 1, A Dorn 1, R Masciadri 1, S Jolidon 1, W F Richter 1, A Guenzi 1, M A Girometta 1, H Urwyler 1, W Huber 1, S Thaithong 1, W Peters 1
PMCID: PMC163428  PMID: 8843292

Abstract

We have synthesized several 4-aminoquinolines with shortened side chains that retain activity against chloroquine-resistant isolates of Plasmodium falciparum malaria (W. Hofheinz, C. Jaquet, and S. Jolidon, European patent 94116281.0, June 1995). We report here an assessment of the activities of four selected compounds containing ethyl, propyl, and isopropyl side chains. Reasonable in vitro activity (50% inhibitory concentration, < 100 nM) against chloroquine-resistant P. falciparum strains was consistently observed, and the compounds performed well in a variety of plasmodium berghei animal models. However, some potential drawbacks of these compounds became evident upon in-depth testing. In vitro analysis of more than 70 isolates of P. falciparum and studies with a mouse in vivo model suggested a degree of cross-resistance with chloroquine. In addition, pharmacokinetic analysis demonstrated the formation of N-dealkylated metabolites of these compounds. These metabolites are similarly active against chloroquine-susceptible strains but are much less active against chloroquine-resistant strains. Thus, the clinical dosing required for these compounds would probably be greater for chloroquine-resistant strains than for chloroquine-susceptible strains. The clinical potential of these compounds is discussed within the context of chloroquine's low therapeutic ratio and toxicity.

Full Text

The Full Text of this article is available as a PDF (283.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asawamahasakda W., Ittarat I., Chang C. C., McElroy P., Meshnick S. R. Effects of antimalarials and protease inhibitors on plasmodial hemozoin production. Mol Biochem Parasitol. 1994 Oct;67(2):183–191. doi: 10.1016/0166-6851(94)00128-6. [DOI] [PubMed] [Google Scholar]
  2. Basco L. K., Andersen S. L., Milhous W. K., Le Bras J., Vennerstrom J. L. In vitro activity of bisquinoline WR268,668 against African clones and isolates of Plasmodium falciparum. Am J Trop Med Hyg. 1994 Feb;50(2):200–205. doi: 10.4269/ajtmh.1994.50.200. [DOI] [PubMed] [Google Scholar]
  3. Bitonti A. J., Sjoerdsma A., McCann P. P., Kyle D. E., Oduola A. M., Rossan R. N., Milhous W. K., Davidson D. E., Jr Reversal of chloroquine resistance in malaria parasite Plasmodium falciparum by desipramine. Science. 1988 Dec 2;242(4883):1301–1303. doi: 10.1126/science.3057629. [DOI] [PubMed] [Google Scholar]
  4. Björkman A., Phillips-Howard P. A. The epidemiology of drug-resistant malaria. Trans R Soc Trop Med Hyg. 1990 Mar-Apr;84(2):177–180. doi: 10.1016/0035-9203(90)90246-b. [DOI] [PubMed] [Google Scholar]
  5. Cowman A. F., Foote S. J. Chemotherapy and drug resistance in malaria. Int J Parasitol. 1990 Jul;20(4):503–513. doi: 10.1016/0020-7519(90)90198-v. [DOI] [PubMed] [Google Scholar]
  6. Desjardins R. E., Canfield C. J., Haynes J. D., Chulay J. D. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother. 1979 Dec;16(6):710–718. doi: 10.1128/aac.16.6.710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dorn A., Stoffel R., Matile H., Bubendorf A., Ridley R. G. Malarial haemozoin/beta-haematin supports haem polymerization in the absence of protein. Nature. 1995 Mar 16;374(6519):269–271. doi: 10.1038/374269a0. [DOI] [PubMed] [Google Scholar]
  8. Fontanet A. L., Johnston B. D., Walker A. M., Bergqvist Y., Hellgren U., Rooney W. Falciparum malaria in eastern Thailand: a randomized trial of the efficacy of a single dose of mefloquine. Bull World Health Organ. 1994;72(1):73–78. [PMC free article] [PubMed] [Google Scholar]
  9. Fontanet A. L., Johnston D. B., Walker A. M., Rooney W., Thimasarn K., Sturchler D., Macdonald M., Hours M., Wirth D. F. High prevalence of mefloquine-resistant falciparum malaria in eastern Thailand. Bull World Health Organ. 1993;71(3-4):377–383. [PMC free article] [PubMed] [Google Scholar]
  10. Geary T. G., Jensen J. B. Lack of cross-resistance to 4-aminoquinolines in chloroquine-resistant Plasmodium falciparum in vitro. J Parasitol. 1983 Feb;69(1):97–105. [PubMed] [Google Scholar]
  11. Good M. I., Shader R. I. Lethality and behavioral side effects of chloroquine. J Clin Psychopharmacol. 1982 Feb;2(1):40–47. doi: 10.1097/00004714-198202000-00005. [DOI] [PubMed] [Google Scholar]
  12. Huber W., Hurt N., Mshinda H., Jaquet C., Koella J. C., Tanner M. Sensitivity of Plasmodium falciparum field-isolates from Tanzania to chloroquine, mefloquine and pyrimethamine during in vitro cultivation. Acta Trop. 1993 Jan;52(4):313–316. doi: 10.1016/0001-706x(93)90016-5. [DOI] [PubMed] [Google Scholar]
  13. Hudson A. T. Atovaquone - a novel broad-spectrum anti-infective drug. Parasitol Today. 1993 Feb;9(2):66–68. doi: 10.1016/0169-4758(93)90040-m. [DOI] [PubMed] [Google Scholar]
  14. Kelly J. C., Wasserman G. S., Bernard W. D., Schultz C., Knapp J. Chloroquine poisoning in a child. Ann Emerg Med. 1990 Jan;19(1):47–50. doi: 10.1016/s0196-0644(05)82141-9. [DOI] [PubMed] [Google Scholar]
  15. Nosten F., Price R. N. New antimalarials. A risk-benefit analysis. Drug Saf. 1995 Apr;12(4):264–273. doi: 10.2165/00002018-199512040-00006. [DOI] [PubMed] [Google Scholar]
  16. Palmer K. J., Holliday S. M., Brogden R. N. Mefloquine. A review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1993 Mar;45(3):430–475. doi: 10.2165/00003495-199345030-00009. [DOI] [PubMed] [Google Scholar]
  17. Peters W. The chemotherapy of rodent malaria, XXII. The value of drug-resistant strains of P. berghei in screening for blood schizontocidal activity. Ann Trop Med Parasitol. 1975 Jun;69(2):155–171. [PubMed] [Google Scholar]
  18. Slater A. F., Cerami A. Inhibition by chloroquine of a novel haem polymerase enzyme activity in malaria trophozoites. Nature. 1992 Jan 9;355(6356):167–169. doi: 10.1038/355167a0. [DOI] [PubMed] [Google Scholar]
  19. Slater A. F. Chloroquine: mechanism of drug action and resistance in Plasmodium falciparum. Pharmacol Ther. 1993 Feb-Mar;57(2-3):203–235. doi: 10.1016/0163-7258(93)90056-j. [DOI] [PubMed] [Google Scholar]
  20. Sullivan D. J., Jr, Gluzman I. Y., Goldberg D. E. Plasmodium hemozoin formation mediated by histidine-rich proteins. Science. 1996 Jan 12;271(5246):219–222. doi: 10.1126/science.271.5246.219. [DOI] [PubMed] [Google Scholar]
  21. Trager W., Jensen J. B. Human malaria parasites in continuous culture. Science. 1976 Aug 20;193(4254):673–675. doi: 10.1126/science.781840. [DOI] [PubMed] [Google Scholar]
  22. White N. J. Antimalarial drug resistance: the pace quickens. J Antimicrob Chemother. 1992 Nov;30(5):571–585. doi: 10.1093/jac/30.5.571. [DOI] [PubMed] [Google Scholar]
  23. Yayon A., Cabantchik Z. I., Ginsburg H. Susceptibility of human malaria parasites to chloroquine is pH dependent. Proc Natl Acad Sci U S A. 1985 May;82(9):2784–2788. doi: 10.1073/pnas.82.9.2784. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. van Es H. H., Skamene E., Schurr E. Chemotherapy of malaria: a battle against all odds? Clin Invest Med. 1993 Aug;16(4):285–293. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES